CytoReason: Funding, Investors & Team (Sep 2026)
CytoReason develops a cell-centered computational model of the human body designed to discover complex patterns in biological data. The company collects proprietary data from pharma companies and uses it to simulate human diseases tissue by tissue, cell by cell. With CytoReason’s massive database and AI-led platform, pharma and biotech companies identify new opportunities, shorten trial phases, reduce development costs and increase the likelihood of approval.
CytoReason has raised $100M across 2 funding rounds on record, the most recent a Series B of $80.0M announced in Jul 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CytoReason Company Profile and Key Stats
Latest funding round on record: Jul 2024.
CytoReason Funding Rounds
CytoReason raised $20.0M in a Corporate Round announced in Sep 2022.
1.8 years later, a Series B of $80.0M was announced in Jul 2024.
CytoReason Founders and Leadership Team
Contact details for the CytoReason team: 1 of 2 have an email address on file.
Start 14-day free trial →CytoReason Funding Compared to Other Biotechnology Startups
CytoReason's latest round of $80.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CytoReason in Biotechnology and Tel Aviv
Companies Similar to CytoReason
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
CytoReason Funding FAQs
What does CytoReason do?
CytoReason develops a cell-centered computational model of the human body designed to discover complex patterns in biological data. The company collects proprietary data from pharma companies and uses it to simulate human diseases tissue by tissue, cell by cell. With CytoReason’s massive database and AI-led platform, pharma and biotech companies identify new opportunities, shorten trial phases, reduce development costs and increase the likelihood of approval.
How much funding has CytoReason raised?
CytoReason has raised $100M across 2 rounds on record. The most recent is a Series B of $80.0M announced in Jul 2024.
When did CytoReason last raise funding?
CytoReason's most recent funding round on record is a Series B of $80.0M, announced in Jul 2024.
Who founded CytoReason?
FundedIQ lists David Harel (Founder), Sara Peleg (Founder) at CytoReason.
Where is CytoReason headquartered?
CytoReason is based in Tel Aviv, Israel.
How many employees does CytoReason have?
CytoReason is in the 51-100 employee band.
How does CytoReason's funding compare to other Biotechnology startups?
CytoReason's latest round of $80.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's CytoReason Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CytoReason is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.